107 results
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
25 May 22
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
4:09pm
to close on or about May 27, 2022, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Chinook … historical facts, including, but not limited to, statements regarding the satisfaction of customary closing conditions related to the offering
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
10 Nov 21
Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering
5:24pm
. The offering is expected to close on or about November 15, 2021, subject to the satisfaction of customary closing conditions. All of the securities … contained herein that do not describe historical facts, including, but not limited to, statements regarding the satisfaction of customary closing
DRS
EX-10
KDNY
Chinook Therapeutics Inc
19 Dec 14
Draft registration statement
12:00am
, satisfaction of all tax withholding obligations, and such other representations and agreements as may be required by the Administrator. The Exercise Price may … as the Administrator may require for the satisfaction of any federal,
-2-
state, and local income and employment tax withholding requirements and any
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
3 Aug 20
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results
4:17pm
definitive merger agreement with Chinook Therapeutics, which is expected to close in the second half of 2020, subject to the satisfaction or waiver … a pipeline of precision medicines for kidney diseases, led by atrasentan and BION-1301 in IgAN, assuming satisfaction of the conditions to closing
425
KDNY
Chinook Therapeutics Inc
3 Aug 20
Business combination disclosure
4:35pm
definitive merger agreement with Chinook Therapeutics, which is expected to close in the second half of 2020, subject to the satisfaction or waiver … and advance a pipeline of precision medicines for kidney diseases, led by atrasentan and BION-1301 in IgAN, assuming satisfaction of the conditions to closing
8-K
3bdldq3v c0ae2dkuxo3
2 Jun 20
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
9:19am
425
vi4nyr3mngaapntb892e
2 Jun 20
Business combination disclosure
9:17am
425
3lltby9n0 zeoyf
18 Aug 20
Business combination disclosure
4:48pm
8-K/A
EX-99.1
oxx2so53lrz
5 Nov 20
Index to Chinook Consolidated Financial Statements
4:58pm
8-K
EX-99.1
k17ely50k
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
8-K
EX-2.1
co2 0uxkiho
18 Aug 20
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-2.1
8qlmg5mll
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
DEFA14A
w67kgn xrpfgyhwawo
12 Jun 23
Additional proxy soliciting materials
7:05am
S-3ASR
EX-4.4
1lbpeyaw4c
24 May 22
Automatic shelf registration
4:01pm
425
m25ymg
21 Sep 20
Business combination disclosure
6:08am